Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Pharmacotherapy and individualization in pediatric HSCT

Jaap Jan Boelens • 20 Aug 2020
EBMT 2020
General Busulfan Fludarabine

Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses pharmacotherapy in pediatric hematopoietic stem cell transplantation (HSCT) and how individualized dosing in HSCT may improve outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jaap Jan Boelens

4:54
Predicting immune reconstitution following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:20
Second cord blood transplant for patients who relapse following alloHSCT
Jaap Jan Boelens • 24 Apr 2022
4:53
The influence of the pulmonary microbiome on outcomes after alloHSCT
Jaap Jan Boelens • 24 Apr 2022
3:23
PARACHUTE trial: ATG in HCST
Jaap Jan Boelens • 1 Sep 2020

Related Videos

2:09
The difficulty in developing predictive potency assays
Valentin Ortiz-Maldonado • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals